Business Context and Reporting Period
This Form 6-K was filed by BioCancell Ltd. (also referenced as Chemomab Therapeutics Ltd. in metadata) on August 13, 2012. The registrant is a foreign private issuer based in Jerusalem, Israel, filing under Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
The primary material event disclosed is the delay in the listing of the Company's securities on the Tel Aviv Stock Exchange Ltd. Consequently, the first trading day was postponed from the originally anticipated date to August 14, 2012.
Guidance, Outlook, and Risks
Management announced that Ordinary Shares, Series 1 Warrants, and Series 2 Warrants are expected to commence trading on August 14, 2012. The filing does not contain specific forward-looking guidance, risk factors, or discussion of unusual items beyond the listing delay.
Investor Verification Checklist
- Confirm the actual commencement of trading for Ordinary Shares and Warrants on the Tel Aviv Stock Exchange on August 14, 2012.
- Verify the ticker symbols assigned to the Ordinary Shares, Series 1 Warrants, and Series 2 Warrants upon listing.
- Review subsequent filings for any further delays or changes to the trading schedule.